Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ping Zhang"'
Autor:
Yan-Li Zhao, Jia-Rui Zhou, Yue Lu, Xing-Yu Cao, Peihua Lu, Jian-Ping Zhang, Huili Zhu, Zhi-Jie Wei, De-Yan Liu
Publikováno v:
Blood. 136:18-19
Introduction SIL-TAL1 rearrangement is relatively common among patients with T-cell acute lymphoblastic leukemia (T-ALL). Pediatric patients with SIL-TL1 positive T-ALL generally have a poor response to early intensive treatment and a lower median re
Autor:
Jian-Ping Zhang, Rui-Juan Sun, Peihua Lu, Junfang Yang, Xian Zhang, Yan-Li Zhao, Jingjing Li, Min Xiong, Jia-Rui Zhou, De-Yan Liu, Yue Lu, Xing-Yu Cao, Zhi-Jie Wei
Publikováno v:
Blood. 136:40-41
Introduction Current available treatments are limited once patients with B-ALL relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT). While chimeric antigen receptor (CAR) T-cell therapy offers a chance of remission, long-t
Autor:
Madan Jagasia, Tae Kon Kim, Jonathan M. Irish, Kate Chilson, Albert C. Yeh, Lynn Onstad, Ping Zhang, Sierra Barone, Geoff R. Hill, Anupama Reddy, Kimberly B. Dahlman, Stephanie J. Lee
Publikováno v:
Blood. 136:15-16
Background: Cytomegalovirus (CMV) serostatus is associated with transplant related mortality, relapse and survival following allogeneic stem cell transplant (SCT). Prior studies have demonstrated that CMV seronegative recipients (R-) receiving a CMV
Autor:
Geoffrey R. Hill, Andrew D. Clouston, Stefan Rose-John, Karshing Chang, Juan Hidalgo, Motoko Koyama, Rachel D. Kuns, Simone A. Minnie, Andrew N. Wilkinson, Antiopi Varelias, Andrea S. Henden, Ping Zhang, Kathleen S. Ensbey, Kate H. Gartlan, Slavica Vuckovic
Publikováno v:
Blood. 134(23)
Graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloSCT) is characterized by interleukin-6 (IL-6) dysregulation. IL-6 can mediate effects via various pathways, including classical, trans, and cluster signaling. Given the
Autor:
De-Yan Liu, Fang Xu, Min Xiong, Dao-Pei Lu, Zhi-Jie Wei, Jia-Rui Zhou, Yue Lu, Jian-Ping Zhang, Peihua Lu, Yan-Li Zhao, Xing-Yu Cao, Rui-Juan Sun
Publikováno v:
Blood. 134:2047-2047
Background: The outcomes of alternative donor haematopoietic stem cell Transplantation(HSCT)for Inherited bone marrow failure syndromes(IBMFS) have not been well described,especially the conditioning regimens are major challenges ,each disease type h
Autor:
Jian-Ping Zhang, Yue Lu, Min Xiong, Yan-Li Zhao, Hongxing Liu, Jia-Rui Zhou, De-Yan Liu, Zhi-Jie Wei, Rui-Juan Sun, Xing-Yu Cao
Publikováno v:
Blood. 132:5786-5786
The level of minimal residual disease (MRD) is one of the most important prognostic indicators for acute lymphoblastic leukemia (ALL). In this study, the data about 390 cases of ALL patients who obtained MRD negative after chemotherapy or CART therap
Autor:
Yan-Li Zhao, De-Yan Liu, Yue Lu, Junfang Yang, Xian Zhang, Jia-Rui Zhou, Xing-Yu Cao, Hui Wang, Zhi-Jie Wei, Hongxing Liu, Dao-Pei Lu, Rui-Juan Sun, Jian-Ping Zhang, Min Xiong, Peihua Lu
Publikováno v:
Blood. 132:2660-2660
Introduction: CD19-CAR-T cells induce high rates of initial response among patients with refractory/relapsed and MRD positive high risk B-cell acute lymphoblastic leukemia (B-ALL). Afterwards allogeneic hematopoietic stem cell transplantation (HSCT)
Autor:
Kate H. Gartlan, Ping Zhang, Nicholas D. Huntington, Marta Chesi, Kate A. Markey, Rachel D. Kuns, Kelly R. Locke, Antiopi Varelias, John J. Miles, Mark J. Smyth, Thomas S. Watkins, Slavica Vuckovic, Simone A. Minnie, Geoffrey R. Hill, David D. Smith, Camille Guillerey
Publikováno v:
Blood. 132:2031-2031
Autologous stem cell transplantation (ASCT) remains an important consolidation treatment for multiple myeloma (MM) patients, even in the era of novel agents. The prolongation of plateau-phase induced by ASCT is generally attributed to intensive cytor
Autor:
Fanyong Lv, Peihua Lu, Jian-Ping Zhang, Xiaosu Zhou, Xin-an Lu, Ting He, Junfang Yang, Xian Zhang, Min Xiong
Publikováno v:
Blood. 132:280-280
Introduction: CD19 CAR-T therapy is effective for B-cell ALL. However, whether patients (pts) with EMD, High Leukemia Burden (HLB), TP53 mutation, BCR-ABL (+) mutation, or post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse ca
Autor:
Rong Liu, Lujia Dong, Heng-Xiang Wang, Zhi-Yong Gao, Tong-Hua Yang, Lung-Ji Chang, Ting Liu, Huyong Zheng, Le-Ping Zhang, Yu-Hong Chen, Xun Lai, Jing-Bo Wang, Jian-Ping Zhang, Ting Niu, He Huang, Li Gao, Dao-Pei Lu
Publikováno v:
Blood. 126:3774-3774
Background: Relapsed/refractory leukaemia is associated with poor prognosis. T cells genetically modified to express CD19-specific chimeric antigen receptor (CD19CAR) in patients (pts) with chronic lymphoblastic leukemia (CLL) and acute lymphoblastic